regulation also contributes to the function of key proteins that modulate macrophage activation. As such, the study of alternative splicing (AS), or differential inclusion of exons into multiple mature mRNA transcripts, [17] [18] [19] may provide new insights into this process given the potential for functional differences in the translated protein products. Such study may be of particular importance in the human context given the rapid evolution of AS in primate species. 20, 21 AS occurs in >95% of human multiexon genes, enhancing the proteomic diversity encoded by the genome. Often, AS profiles are tissue or cell type specific [22] [23] [24] [25] [26] with variable interspecies conservation, 20, 21, 27 and these patterns are coordinated by a balance of the expression or activity of splicing factors, which are RNA-binding proteins that bind to cis-regulatory elements near alternative exons. This binding affects recruitment of the spliceosome to pre-mRNA splice sites and influences whether an alternative exon is incorporated into the final transcript. 28 In addition, AS patterns can be disrupted by genetic variants affecting the splicing code of these cis-regulatory elements and the actual splice sites recognized during exon inclusion. 26, 29, 30 As a regulatory process, differential AS on a transcriptomewide scale has been shown to occur during cellular phenotypic changes, eg, during epithelial to mesenchymal transition, somatic cell reprogramming for induced pluripotent stem cell generation, neuronal and cardiomyocyte development, and T-cell activation. [31] [32] [33] [34] [35] Therefore, we hypothesized that aberrant splicing of a network of genes may contribute to pathogenic M1 activation in cardiometabolic diseases. Although a few studies have used RNA-sequencing (RNA-seq) to profile the transcriptomes of M1 and M2 macrophages, [36] [37] [38] differential AS during macrophage activation and its relationship to cardiometabolic diseases has not yet been explored.
To address this gap in knowledge, we sought to determine the extent to which AS and its regulation modulate human macrophage phenotype, with a focus on the cardiometabolic disease-associated M1 macrophage activation paradigm. The aims of our study were 3-fold: (1) to characterize the AS landscapes of macrophage activation in primary human monocyte-derived macrophages (HMDMs), (2) to identify splicing targets and splicing factors as novel targets for cardiometabolic traits using genetic variant data, and (3) to validate induced pluripotent stem cell-derived macrophages (iPSDMs) as a cellular model system for investigating macrophage-relevant AS events. Here, we report the first comprehensive assessment of AS in human macrophage activation with translational context for the study of human cardiometabolic diseases.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Macrophage Activation Leads to Distinct Transcriptomic Landscapes
To study the full spectrum of transcriptomic changes occurring during macrophage activation, we performed deep RNA-seq (≈130 million reads per sample) of resting M0-HMDMs, M1-HMDMs (lipopolysaccharide/interferon-γ), and M2-HMDMs (interleukin-4) from 6 healthy human participants as previously described, analyzing differences between resting and activated HMDMs ( Figure 1A, GSE55536 ). 16 We characterized elsewhere the divergent transcript-level profiles of M1-HMDM and M2-HMDM activation, including comprehensive differential gene expression of M1 and M2 mRNA markers and enrichment of different gene ontology pathways for each condition (pathways are summarized in Table I in the online-only Data Supplement). 16 In this previous analysis, we had found 3860 genes to be differentially expressed in M1 activation, whereas only 357 genes were differentially expressed in M2 activation. 16 To explore whether macrophage activation also involved changes in AS patterns, we analyzed our RNA-seq data using the PennDiff, DEXseq, and IUTA [39] [40] [41] software programs to detect differential AS between M0-HMDMs and M1-HMDMs, our primary analysis, and between M0-HMDMs and M2-HMDMs in our secondary analysis. Three different software programs were used to maximize the number of detected AS events and to analyze AS on both the exon-level (DEXseq and PennDiff) and the whole-gene level (degree of AS occurring at a locus, IUTA and PennDiff). We extended this approach to RNA-seq of peripheral blood mononuclear cells (PBMCs) collected before and after intravenous bolus of 1-ng lipopolysaccharide per kg body mass exposure in 8 healthy participants in a human experimental endotoxemia trial (GSE50792; as of September 27, 2016, this RNA-seq dataset has been assigned a new GEO accession number account, GSE87290.). [42] [43] [44] The PBMC transcriptomic profiles served as a basis to probe whether M1-HMDM AS changes occurred uniquely within the macrophage system or more broadly in other inflamed hematopoietic cells and contexts. Given that M1-HMDM activation induced differential expression of genes enriched for pathways distinct from those seen in M2-HMDM activation and in postlipopolysaccharide PBMCs ( Table I in the online-only Data Supplement), 16 we hypothesized that AS patterns would also manifest in a cell-specific and stimulation-specific manner.
Differential AS events in each experimental condition (M0versus M1-HMDMs, M0-versus M2-HMDMs, or pre-versus postlipopolysaccharide PBMCs; Figure 1A ) were considered significant if they were called by either DEXseq or PennDiff to have >5% Δexon inclusion level at a false discovery rate P<0.05 as determined by the Benjamini-Hochberg method. 39, 40 We found that of the 3 experimental conditions, M1-HMDM activation was accompanied by the most dynamic landscape for AS differences: the 233 AS events for M1-HMDM activation, which were predominately single cassette exon events, amounted to (1) >20× the number of events occurring in RNA-sequencing (RNA-seq) differential alternative splicing (AS) analysis of human monocyte-derived macrophages (HMDMs), induced pluripotent stem cell derived macrophages (iPSDMs), and peripheral blood mononuclear cells (PBMCs). A, Overview of cell types studied. PBMCs were isolated from human donors and were differentiated into primary M0-HMDMs, reprogrammed into iPSCs with subsequent macrophage differentiation, or stimulated with lipopolysaccharide (LPS) in vivo in an evoked endotoxemia experiment. M0-HMDMs and M0-iPSDMs were then activated to M1 or M2 states. B, Distribution of differential AS and alternative promoter (AP) events for each experimental condition and cell type. C, Venn diagrams of single cassette exon (CE) events for each type of cell stimulation show distinct differential AS patterns for each condition. A5SS indicates alternative 5′ splice site; A3SS, alternative 3′ splice site; MEE, mutually exclusive exons; and RI, retained intron.
M2-HMDM activation and (2) >2× the number of events occurring in lipopolysaccharide-stimulation of PBMCs ( Figure 1B ; Tables II-IV in the online-only Data Supplement) . Although on a different scale, this pattern echoes what we had seen in differential expression of genes for M1 versus M2 activation. The computational programs we used also allowed us to detect alternative promoter usage in addition to AS events, and we found that the majority of isoform-switching across all experimental contexts involved alternative promoter sites ( Figure 1B ; Tables II-IV in the online-only Data Supplement). Previous studies have reported widespread usage of alternative promoters in the human genome, including differential alternative promoter events in M1-HMDMs, 36, 45 and within genes using alternative promoters, concurrent AS events have been seen. 46, 47 Indeed, for M1-HMDM activation, 1-sided Fisher exact tests revealed robust enrichment of alternative promoter events not only in genes that were differentially expressed (P=2.8×10 -6 ) but even more so in genes undergoing differential AS (P<2.2×10 -16 ). Enrichment of AS events in differentially expressed genes was less robust (P=0.02; Figure   I in the online-only Data Supplement). Alternative promoter sites in M1-HMDM activation, however, had significant overlap with postlipopolysaccharide PBMCs (Table VI in the onlineonly Data Supplement), suggesting that unlike AS (see below), alternative promoter events may not be driving most of the macrophage-specific changes in M1-HMDM activation.
Differential AS Patterns Are Specific to Cell Type and Stimulus
Differentially Spliced Genes in M1-HMDM Activation Are Enriched for Inflammatory Pathways
After establishing that M1-HMDM activation resulted in its own pattern of transcriptomic changes, we evaluated whether differential AS occurred in genes enriched for particular pathways specific to M1-HMDM activation. We interrogated differentially spliced genes for each type of cell stimulation using ingenuity pathway analysis and found distinct pathway enrichment patterns for each experimental condition. Top pathways in M1-HMDM activation were consistent with intracellular responses to inflammation and included apoptosis as well as signaling in the AKT, mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 5 (CDK5), extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), and NF-κB pathways ( Table 1 ). These pathways contrasted with those involved in PBMC inflammation and M2-HMDM activation, which both included metabolic pathways such as lipoate modification and glycogen synthesis, respectively (Table 1) . Top pathways in genes undergoing differential AS for each condition also differed from those for genes differentially expressed in the corresponding condition; as an example, in M1-HMDM activation, the top pathways for alternatively spliced genes including apoptosis and mTOR signaling differ from top pathways for differentially expressed genes ( Table 1 ; Table I in the online-only Data Supplement). Furthermore, the top functions enriched in networks of differentially spliced genes for each condition also differed. For example, angiogenesis and atherosclerosis predominated networks in M1-HMDM activation, whereas fatty acid metabolism and wound healing predominated M2-HMDM networks, and cellular migration and adhesion were top functions of postlipopolysaccharide PBMC networks (Figures IIA-IIC in the online-only Data Supplement).
Cassette Exon Events Occur in Celland Stimulus-Specific Manner
To determine whether specific differential AS patterns are unique to cell type and condition, we focused on single cassette exons, the most common type of differential AS we found in our experiments ( Figure 1B ). M1-HMDM activation had only 2 out of its 123 cassette exon events overlapping with those occurring in M2-HMDM activation and only 14 overlapping with those in lipopolysaccharide-stimulated PBMCs ( Figure 1C ). We selected a subset of cassette exon events observed in M1-HMDM activation for reverse transcriptase polymerase chain reaction validation prioritized based on biological relevance (eg, phospholipase-D [PLD1] and glycogen synthase kinase 3 beta [GSK3B] for macrophage metabolism; beta arrestin 1 [ARRB1], CD74, and TLR4 for immune response). This confirmed that these splicing changes were Hypoxia signaling in the cardiovascular system 1.57
Insulin receptor signaling 1.51
Nitric oxide signaling in the cardiovascular system 1.51
Pathways identified by ingenuity pathway analysis for genes that are differentially spliced in each experimental condition. CDK5 indicates cyclindependent kinase 5; ERK, extracellular signal-regulated kinase; HMDM, human monocyte-derived macrophage; IGF-1, insulin-like growth factor-1; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; PBMC, peripheral blood mononuclear cells; PEDF, pigment epithelium-derived factor; PKR, protein kinase R; PPARγ, peroxisome proliferator-activated receptor gamma; TNFR1, tumor necrosis factor receptor 1; and TWEAK, TNF-related weak inducer of apoptosis. July 2016 specifically seen in M1-HMDMs but not in M2-HMDMs ( Figures 2A and 2B and 3A). Differential AS of the alternative exons for these genes may have biological relevance as they encode a portion of the functional domains of the corresponding proteins such as the protein kinase domain of GSK3B and the TRAF6 (TNF receptor-associated factor) interacting domain of ARRB1 (Figures IV and V in the online-only Data Supplement). These AS patterns differed not only from those for reparative M2-HMDMs but also from patterns observed during inflammatory stimulation of several other cells and tissues; for example, differential AS events seen in M1-HMDMs were not seen in visualization of our RNA-seq data for inflamed PBMCs, adipose, or renal epithelial cells ( Figure III in the online-only Data Supplement).
Because these differential AS events occur specifically in M1-HMDM activation, we hypothesized that they play a functional role during this phenotypic transition. CD74 has macrophage-relevant roles in antigen presentation, 48 and increased inclusion of CD74's exon 7, which encodes the proteolytic thyroglobulin domain of the CD74 protein ( Figure V in the online-only Data Supplement), is observed during M1-HMDM ( Figure 3A ; Table II in the online-only Data Supplement). To test whether exon 7 is involved in the inflammatory M1 response, we used antisense locked nucleic acid oligonucleotides to target exon 7 and found that compared with nontargeting control, knockdown of the exon 7-containing isoform induced even higher IL6 and CCL5 mRNA expression after 6 hours of 100 ng/mL lipopolysaccharide with 20 ng/mL interferon-γ stimulation of HMDMs ( Figure VIB in the online-only Data Supplement) and almost complete macrophage detachment by 18 hours of stimulation (data not shown), suggesting that the inclusion isoform plays a role in modulating the M1-HMDM response.
Splicing Factors in M1-HMDM Activation
After determining that M1-HMDMs have a distinct AS pattern, we focused on potential splicing factors, which regulate tissue-specific splicing, 23, 26, 49 that might contribute to these differences. Performing RNA-binding motif enrichment analysis for simple cassette exon events in M1-HMDM activation, we found that regions within 300 bp of a differentially spliced exon were enriched for binding sites of 12 splicing factors listed in Table 2 . Enrichment for these splicing factor binding sites was not found near differentially spliced exons in M2-HMDM activation and lipopolysaccharide-stimulation of PBMCs. Because splicing factors that regulate smaller subsets of transcripts may not be identified through the enrichment testing for all differential AS events, we examined the RNAseq data of M0-HMDMs versus M1-HMDMs for splicing factor gene expression patterns. Of 220 known and putative splicing factors, 52 37 were differentially expressed (>1.5-fold change, false discovery rate <0.05), with 14 upregulated in M1-HMDM activation ( Table VII in the online-only Data Supplement), whereas no splicing factors were differentially expressed in M2-HMDM activation, consistent with the more dynamic and diverse changes in AS in M1-HMDMs. Although splicing factors do not necessarily need to be differentially expressed to have differential functionality in one condition over another, we used differential expression as a criterion for selecting M1-HMDM-modulated splicing factor CELF1 for further study, as described below. 
Common Genetic Variants Associated With Cardiometabolic Traits Highlight Potential Modulators of M1 Macrophage Activation Through AS
Because previous studies have shown that common genetic variants associated with cardiometabolic traits can have functional effects in disease pathophysiology, 53, 54 we probed the relationship between trait-associated variants and differential AS in each cell condition.
Variants in Differentially Spliced Genes During M1-HMDM Activation
To determine which of the AS events occurring in macrophage activation and PBMC stimulation might be implicated in cardiometabolic diseases, we interrogated the genomic loci of these differentially spliced genes for cardiometabolic trait-associated single nucleotide polymorphisms (SNPs) in publicly available genome-wide association study databases. [55] [56] [57] [58] Our primary hypothesis for this analysis was that (1) trait-associated SNPs may identify genes differentially spliced in M1-HMDM activation that contribute to pathogenic M1 activation, and (2) a subset of these SNPs may directly cause disease-promoting splicing events by altering the splicing code. As a complementary study, we also interrogated SNPs in genes differentially spliced in M2-HMDM activation and in postlipopolysaccharide PBMCs. After Bonferroni correction for the number of SNPs tested, we identified 28 tag SNPs that fall within the loci of genes differentially spliced in M1-HMDM activation and are associated with cardiometabolic traits including lipid phenotypes, obesity, and coronary artery disease (Table 3) ; the tag SNPs also fall within loci of genes with alternative promoter usage. These SNPs, which are mostly intronic and >300 bp away from splice sites, have low linkage disequilibrium (LD) with each other and are located throughout the genome at metabolism-related genes such as PLD1 and GSK3B or inflammation-related genes such as TAX1BP1, FBXL19, and ALOX5. Interestingly, Figure 3 . Induced pluripotent stem cell derived macrophages (iPSDMs) recapitulate alternative splicing (AS) events in M1 activation. A, Reverse transcriptase polymerase chain reaction (PCR) validation of bioinformatically identified differential AS events in human monocyte-derived macrophages (HMDMs) and iPSDMs. % exon inclusion and SD calculated from gel densitometry of (inclusion PCR product)/ (total PCR product). B, Correlation plot of AS events predicted for each gene (calculated to be value θ) in M1-HMDM vs M1-iPSDM. Spearman ρ=0.77, P<0.001. C, Correlation plot of differential expression of splicing factors on the log(2) scale. Spearman ρ=0.78, P<0.001. TLR indicates Toll-like receptor.
trait-associated SNPs were not found in genes differentially spliced in M2-HMDM activation, and although GSK3B, GUCY1A3, and SYNE1 have tag SNPs for both M1-HMDM AS and postlipopolysaccharide PBMC AS, the tag SNPs for genes alternatively spliced in both inflamed cell populations mostly differed (Table 3 ; Table X in the online-only Data Supplement).
The effects of these SNPs on protein abundance, isoform expression levels, and function remain unknown, but they may exert effects on AS patterns. For example, ALOX5 is identified by the PennDiff software to have 7% more inclusion of exon 13 in M1-HMDM activation (P=5.2×10 -4 ; Table II in the online-only Data Supplement, wiggle file in Figure 4A ) and hosts rs12765320, an SNP associated with circulating highdensity lipoprotein-cholesterol. Because the vast majority of tag SNPs in our analyses do not fall within the splicing regulatory regions of 300 bp flanking an AS site, we performed additional LD analysis using 1000 Genomes SNP data to identify potential SNPs that could affect the splicing code. The intronic tag SNP rs12765320 is in high LD (R 2 ≥ 0.8) with rs56145077, an intronic SNP falling within 300 bp of alternative exon 13 that encodes a portion of the enzyme's lipoxygenase domain ( Figure V in the online-only Data Supplement). rs56145077 lies within bioinformatically identified binding sites of splicing factors SRSF1 (serine/arginine-rich proteinspecific kinase; P=1.8×10 -3 ), RBM45 (RNA-binding motif; P=3.6×10 -2 ), and RBM5 (4.4×10 -2 ), thus potentially affecting the splicing code as the minor allele is predicted to decrease exon 13 inclusion by 32% ( Figure 4A ). Additional tag SNPs in LD with 1000 Genomes SNPs (European data) are listed in Table XI in the online-only Data Supplement.
Variants in Differentially Expressed Splicing Factor Genes During M1-HMDM Activation
In addition to exerting effects on the splicing code of cisregulatory elements, cardiometabolic trait-associated genetic variants may also affect AS if they are located within the loci encoding relevant splicing factors. Among the 37 differentially expressed splicing factor genes during M1-HMDM activation, 7 have SNPs associated with cardiometabolic traits after Bonferroni correction (Table 4 ). CELF1, a splicing factor implicated in other human diseases, 34, 60 has the broadest and most statistically significant associations with cardiometabolic traits including high-density lipoprotein-cholesterol, body mass index, fasting glucose, and type 2 diabetes mellitus ( Table 4 ). We chose to study CELF1 further for the following reasons: (1) its robust associations with multiple cardiometabolic traits, (2) the enrichment of its RNA-binding motif near differentially spliced exons in M1-HMDM activation ( Table 2) , and (3) its differential expression on both the mRNA and the protein levels during M1 activation ( Figure 5A and 5B ).
LD analysis of CELF1's trait-associated tag SNPs revealed that rs11607518 (type 2 diabetes mellitus, adjusted P=2.6×10 -2 ) and rs7933019 (fasting glucose, adjusted P=1.8×10 -3 ) are in high LD (R 2 >0.8) with rs77204316, rs11604233, and rs11039290-SNPs that fall within ChIP-seq binding sites for macrophage-relevant transcription factor C/EBPβ (GSE31621). 61 The location of these trait-associated SNPs at the CELF1 locus within binding sites for an essential macrophage transcription factor and evidence that M1 macrophages are involved in type 2 diabetes mellitus 62,63 prompted us to ask whether CELF1 plays a role in modulating M1 activation. First, we confirmed that CELF1 mRNA ( Figure 5A ) and protein ( Figure 5B ) expression increased during M1-HMDM activation in samples of independent healthy human donors. Next, we performed siRNA-mediated knockdown of CELF1 ( Figure 5C ) and evaluated inflammatory response after HMDM stimulation with lipopolysaccharide and interferon-γ. CELF1 knockdown led to increased expression of a subset of inflammatory markers, including secreted interleukin-1β on cytokine array ( Figure 5D ; P<0.01; Figure VIIB in the online-only Data Supplement); mRNA expression of IL6 (P=0.04), IRF1 Table 2 RNA-binding motif enrichment identified for splicing factors in the 300-bp regions flanking differentially spliced exons using the Analysis for Motif Enrichment tool of MEME-Suite. 50 Adjusted P values reflect FDR and Bonferroni corrections for multiple testing. FDR was determined using the Benjamini-Hochberg method, 51 and Bonferroni correction entailed dividing the unadjusted P value for the number of tests performed. FDR indicates false discovery rate; RBM, RNA-binding motif; and SRSF, serine/arginine-rich protein-specific kinase.
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(P=0.02), and CXCL10 (P<0.01; Figure VIIA in the online-only Data Supplement); and secreted interleukin-6 and CCL5 ( Figure  VIIC in the online-only Data Supplement; P=0.04 and P=0.03, respectively). These results suggest that CELF1 may modulate a portion of the anti-inflammatory response during M1 activation.
Induced Pluripotent Stem Cell-Derived Macrophages Demonstrate High Fidelity of Differential AS Events
With genetic variation emerging as a significant basis of complex cardiometabolic diseases, 56,58,64,65 the use of differentiated induced pluripotent stem cells, including iPSDMs, to model human diseases has become increasingly important in understanding functional impact and translational implications. 16, 36, [66] [67] [68] Recent studies have demonstrated that genetic variants may be causal in human diseases by inducing aberrant splicing through altering the splicing code (see above), 29, 30, 69 so we evaluated whether the iPSDM system can be a model for studying AS events. We analyzed RNA-seq data for M1-iPSDM and M2-iPSDM activation (derived from the same donors contributing to HMDM RNA-seq; Figure 1A) to determine whether iPSDM cellular models recapitulated the Adjusted P values are corrected for multiple testing. BMI indicates body mass index; CAD, coronary artery disease; CARDIoGRAM, Coronary Artery Disease Genome Wide Replication and Meta-Analysis; FDR, false discovery rate; GIANT, Genetic Investigation of Anthropometric Traits; GLGC, Global Lipids Genetics Consortium; GSK3B, glycogen synthase kinase 3 beta; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MAGIC, Meta-Analyses of Glucose and Insulin-Related Traits Consortium; PLD1, phospholipase-D; TC, total cholesterol; and TG, triglycerides.
*Also present in postlipopolysaccharide peripheral blood mononuclear cells. July 2016
AS profiles for M1-HMDMs and M2-HMDMs. On a transcriptome-wide scale, a strong correlation in gene-level differential AS events (defined as degree of differential isoform expression θ, using identical PennDiff and IUTA criteria as for HMDMs) is seen between M1-HMDMs and M1-iPSDMs (ρ=0.77; P<0.001; Figure 3B ). Reverse transcriptase polymerase chain reaction assays also confirmed fidelity of predicted differences in AS patterns for both M1-HMDMs and M1-iPSDMs (examples from 3 sequenced donors shown in Figure 3A ). Furthermore, a strong correlation in differential expression of splicing factor genes was seen between the 2 cell systems (ρ=0.78; P<0.001; Figure 3C ), indicating that splicing regulation is largely similar between iPSDMs and HMDMs. These results demonstrate that the iPSDM system can be a useful tool in functional genomic interrogation AS events.
Discussion
To our knowledge, this study to characterize comprehensively the AS landscape of human macrophage activation, particularly with respect to cell and phenotypic specificity and cardiometabolic diseases. Although 1 previous study demonstrated that a common genetic variant associated with low-density lipoprotein-cholesterol can alter AS, 69 ours is the first to integrate summary-level data from multiple genomewide association study consortia to explore the relationship between cardiometabolic variants and AS in M1 activation. We present novel evidence that the splicing factor CELF1, mostly studied in the context of muscular dystrophy and cardiomyopathy, plays a role in modulating M1 activation of human macrophages and also harbors genetic variation for multiple cardiometabolic traits. Finally, our iPSDM system provides a reliable cellular model for functional interrogation of human macrophage splicing events facilitating translational study of disease-associated genetic variation in both the splicing code and the splicing factors. Transcriptional programs have been recognized as regulators of macrophage activation, 1, 2, 8, 15, 16 yet little is known about whether isoform-level expression profiles are also distinct for M1 and M2 macrophages. Because knockdown of whole genes may lead to unanticipated off-target effects, identifying disease-relevant isoform-level differences in a tissue-or 61 and histone tail modification marks on ChIP-seq. 59 Yellow highlights indicate positions of SNPs in LD with tag SNPs for type 2 diabetes mellitus (T2DM; green diamond) and fasting glucose (teal circle), notably overlapping C/EBPβ binding sites.
cell-specific manner may open the door for more selective therapeutic targeting in reprogramming macrophage phenotype, a focus of increasing interest in clinical translation. 8, 70, 71 Here, we demonstrated that M1-HMDM activation was indeed associated with many changes on the isoform level, including >200 differential AS events. Although the number of AS events was far fewer than the number of differentially expressed genes in M1 activation, these AS events were enriched for a network of biologically relevant genes involved in macrophage functions such as autophagy (eg, PLD1) 72 and immune processes (eg, CD74 and TLR4), [73] [74] [75] [76] all of which are linked to the modulation of macrophage inflammation. M2 activation also confers a recognized pattern of differential gene expression, 16 but it induces relatively few differential AS events, suggesting that the inflammatory stress response of M1 activation may create more transcriptomic diversity through AS than that of M2 activation. Differential AS events in inflamed PBMCs overlapped minimally with those in M1-HMDMs, reinforcing the concept that stress-induced splicing changes are mostly cell and context specific. After establishing that AS contributes to the transcriptomic response during macrophage activation, the next mechanistic steps to advance clinical translation are to study (1) specific splicing targets and (2) the larger regulatory mechanisms underlying differential AS in macrophage activation. Here, we showed through our proof-of-principle experiment with CD74 isoform-specific knockdown that transcript variants can have major effects on cellular function and survival. Whether transcriptome-wide differential AS events in M1-HMDM activation have systematic functional and pathophysiological significance requires further investigation. It is more likely that genes differentially spliced in M1-HMDM activation can modulate cardiometabolic pathophysiology if they house SNPs associated with relevant traits. The combination of structural mRNA changes in response to environmental challenges and the existence of trait-associated variants within a locus make a case for the potential importance of a gene in macrophage phenotype. We found 28 such tag SNPs within the loci of 21 genes differentially spliced in macrophage M1 activation. A subset of these SNPs are in LD (identifiable via 1000 Genomes 77 data; Table XI in the online-only Data Supplement) with specific variants that fall within regulation sites of AS. They may alter the splicing code and subsequently induce aberrant splicing to generate specific isoforms favoring a disease phenotype, a phenomenon documented for rare and common genetic variants for a variety of human diseases. 29, 69 For example, here we showed that ALOX5, a gene involved in proinflammatory functions and leukotriene synthesis, 78 is predicted to have a decrease in its alternative exon inclusion level in the presence of a minor allele SNP associated with high-density lipoprotein-cholesterol. Further functional validation of this variant in terms of its effect on ALOX5's AS and downstream pathways is warranted. Because the majority of genes alternatively spliced in macrophage activation do not house cardiometabolic variants at their loci, while only a subset of those with trait-associated variants have sites where SNPs may affect splicing efficiency, trait-associated variants likely are not the primary driver of AS in this process. However, tag SNPs, serving as guideposts to identify genes functionally relevant in cardiometabolic traits, may still help identify and prioritize novel targets in studies of macrophage activation within the human disease context.
Beyond specific AS events and specific spliced genes, the expression and function of splicing factors determining isoform switch patterns in a tissue-and cell-specific manner holds promise for novel mechanistic insights and therapeutic translation. We found that M1-associated glucometabolic traits 79 are statistically associated with SNPs at the CELF1 locus overlying binding sites for the macrophage-relevant transcription factor C/EBPβ, suggesting that the regulation of CELF1 gene expression in macrophages may impact human cardiometabolic diseases. Indeed, knockdown of CELF1 levels modulated expression of a subset of M1 markers, suggesting that CELF1 splicing targets are involved in M1 activation. Because AS is a critical process during development, 31, 34, 60 the increased splicing switches that occur in M1 activation may indicate that inflammatory stress induces a dedifferentiation profile. This concept is consistent with our observation of increased M1-HMDM expression of CELF1, which is more highly expressed in the embryonic state. 52, 60 Remarkably, 36% of our bioinformatically identified AS events in M1-HMDM activation overlap with transcripts found to interact with CELF1 in cross-linking and immunoprecipitation sequencing of murine hearts (GSE61892-61893) 60 although cross-linking and immunoprecipitation sequencing within the human macrophage system will need to be performed to confirm experimentally that CELF1 is a regulator of AS in M1 activation.
Beyond splicing factors, additional regulatory mechanisms could be at play in influencing splicing patterns in macrophage biology. As expected, M1-HMDM activation was accompanied by a wealth of alternative promoter usage given that transcriptional regulation has been established as a driving force in determining macrophage phenotype. However, our data show that alternative promoter usage was highly correlated with AS events in the same gene, a poorly studied and understood phenomenon. 46 Future studies are needed to identify whether specific proinflammatory transcription factors interact with splicing factors to orchestrate M1-HMDM isoform switches and whether these switches can be explained by chromatin changes during M1 activation. In this respect, future studies on epigenetics, which have also been implicated in AS, 80 may be informative.
This study has several strengths. First, we took an unbiased approach to discover M1-HMDM differential AS events not previously identified in the literature. Second, our use of primary human macrophages for our primary analysis and for reverse transcriptase polymerase chain reaction validation strengthens the applicability of our findings to human physiology, and thus future clinical translational potential given the species-specific nature of many AS events. 18, 20, 21, 81 Third, we leverage genome-wide association study data for cardiometabolic traits to identify potentially novel modulators of M1 activation in complex human diseases. Fourth, our exploration of whether differential AS events can be recapitulated in the iPSDM system validates the use of this cutting-edge genomic technology for future disease variant-oriented studies of AS in macrophages.
This study also has limitations that suggest further avenues of research. First, although we identified many differential AS events and validated a few for M1-HMDM activation, demonstrating that specific isoforms are necessary for M1 activation was beyond the scope of this work. Second, although we were able to validate splicing changes on the mRNA level, we did not present protein-level data as our attempts to resolve predicted small molecular weight changes and modest isoform shifts using Western blot methods did not yield detectable differences. These differences would be more accurately detected and quantitated by mass spectrometry, which will be used in future targeted follow-up. Also, our use of HMDMs from healthy individuals as a model for M1 and M2 activation may not capture the full spectrum of macrophage-specific transcriptomic changes in chronic cardiometabolic diseases (eg, atherosclerosis) that develop and progress from factors including but not limited to age, genetic background, and other comorbidities. In addition, our analysis of splicing factors lacked human macrophage crosslinking and immunoprecipitation sequencing data, which can help prove that CELF1's effects on the M1 phenotype are via AS rather than other RNA-binding regulatory mechanisms. Finally, our genome-wide association study translation can be considered a starting point to generate experimental data to demonstrate whether the disease-associated SNPs are truly causal in altering splicing patterns and in modulating M1 activation. Future studies on the molecular mechanisms, RNA-binding protein interactions, causal splicing variants, and novel pathways of AS changes in macrophage activation are warranted.
In summary, we show that isoform-level differences help define macrophage phenotype and that the splicing mechanisms for producing isoform switches occur in a cell-and stimulus-specific fashion. Aberrant splicing that leads to deleterious traits may occur in the presence of trait-associated genetic variants that provide a causal link between splicing event and disease-related phenotype. These findings lay the groundwork for future macrophage isoform-specific studies and for evaluating novel causal mechanisms and therapeutic targets in cardiometabolic diseases.
